About the role
The Centre for Phage Research at the University of Leicester is seeking a talented and motivated researcher to join our team. The role offers a chance to be at the forefront of exploring bacteriophages (phages) as novel therapeutic alternatives to antimicrobials.
Bacteriophages are known for their unique ability to attack bacteria with the potential to target and eliminate drug resistant bacterial pathogens.
The successful candidate will join a project to screen phages against Moraxella bovis, a pathogen that causes Bovine Keratoconjunctivitis. This project involves screening of environmental samples, isolating phages active against clinically relevant Moraxella bovis strains and assisting in phage characterization.
About you
The successful applicant will have substantial laboratory-based experience in working with phages and experience of providing guidance and training to others in this field.
Additional information
Informal enquiries are welcome and should be made to Martha Clokie onmrjc1@leicester.ac.uk
Applications for job share will be considered
The University of Leicester has been changing the world, and changing people’s lives, for 100 years. When you join us, you’ll become part of a community of Citizens of Change, which includes not only our staff and our current students but also thousands of Leicester graduates around the world.
As a diverse and forward-thinking employer, we embed the principles of equality, diversity and inclusion into everything we do. That includes not just our core missions of teaching and research, but also our support for staff, students and our local communitythrough our values of Inspiring, Impactful and Inclusive.
We’re committed to the wellbeing of all our staff and to the sustainability of our environment, on our campus and beyond. We offer a competitive salary package, excellent pension scheme and a generous annual leave allowance, along with opportunities to develop your career in a supportive and collaborative environment.
Vacancy terms
Full-time, or job share considered, fixed term contract until 28 February 2025
#J-18808-Ljbffr